Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Results of a Phase 1/2 Study.
Paul G. Richardson(Harvard University), Kenneth C. Anderson(Dana-Farber Cancer Institute), Stephen Hayes(Dana-Farber Cancer Institute), Irene M. Ghobrial(Dana-Farber Cancer Institute), Sagar Lonial(Emory University), Sundar Jagannath(Mount Sinai Hospital), Robin Joyce(Beth Israel Deaconess Medical Center), Lawrence Giove(Saint Vincent Health System), Nikhil C. Munshi(Dana-Farber Cancer Institute), Carol Delaney(Beth Israel Deaconess Medical Center), Robert Knight(King's College London), Deborah Doss(Dana-Farber Cancer Institute), Noopur Raje(Massachusetts General Hospital), David Avigan(Beth Israel Deaconess Medical Center), Andrzej Jakubowiak(University of Chicago Medical Center), Teru Hideshima(Harvard University), Amitabha Mazumder(NYU Langone Health), Robert Schlossman(University of Leeds), Diane Warren(Dana-Farber Cancer Institute), Sarah Kaster(Massachusetts General Hospital), Marisa Lauria(Beth Israel Deaconess Medical Center), Dixie-Lee Esseltine(Millennium Engineering and Integration (United States)), Constantine S. Mitsiades(Dana-Farber Cancer Institute)
Cited by 30
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k